Home
Home

Questcor Pharmaceuticals

Questcor Pays $135 Million to Acquire Rights to a Competitor’s Drug

Questcor Pays $135 Million to Acquire Rights to a Competitor’s Drug
NY Times

Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel

Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel
Seeking Alpha

3 Humongous Health-Care Stocks This Week

3 Humongous Health-Care Stocks This Week
Motley Fool

Questcor - Short Squeeze Starting

Questcor - Short Squeeze Starting
Seeking Alpha

10 Biotech Stocks With A History Of Beating Earning Expectations

10 Biotech Stocks With A History Of Beating Earning Expectations
TheStreet.com

JPMorgan Healthcare Conference Highlights: Questcor Pharmaceuticals

JPMorgan Healthcare Conference Highlights: Questcor Pharmaceuticals
Motley Fool

2 Biotech Short-Squeeze Candidates For The New Year

2 Biotech Short-Squeeze Candidates For The New Year
Seeking Alpha

3 Horrendous Health-Care Stocks This Week

3 Horrendous Health-Care Stocks This Week
Motley Fool

4 Investing Lessons From Questcor's 2012

4 Investing Lessons From Questcor's 2012
Motley Fool

Questcor Pharmaceuticals Inc.: Today's Featured Health Care Laggard

Questcor Pharmaceuticals Inc.: Today's Featured Health Care Laggard
The Street